Drawing for ALPHINIA

USPTO serial 79346041

ALPHINIA

Reviewed by CopyMark Law Group

Reg. 7265299Status 700Registered
Filing date
Status date
Registration date
Jan 9, 2024
Examiner
STRUCK, ROBERT J
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ALPHINIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jennifer A. Visintine

Jennifer A. Visintine Thompson Coburn LLPOne US Bank PlazaSt. Louis, MO 63101UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
042Advisory services relating to immunological product development; benchmarking, namely, technical testing in the field of genetics, biology, biotechnology, microbiology, biochemistry and pharmacy for scientific and medical research purposes; biological research; biotechnological research; biotechnology testing for scientific research purposes; conducting statistical scientific studies in the field of genetics, biology, biotechnology, microbiology, biochemistry and pharmacy; development of new products; development of new products for medical purposes, namely, medicines, pharmaceuticals, therapeutic and immunological products; development and testing of chemical production methods; dna testing services for scientific research purposes; genetic testing for scientific research purposes; genetic research, namely, mammalian genetics research; scientific research in the field of genetics; laboratory testing services, namely, scientific laboratory services; medical laboratory services; laboratory testing services for others, namely, scientific research and analysis in the field of genetics, biology, biotechnology, microbiology, biochemistry and pharmacy; microbiological testing for scientific research purposes; preparation of scientific reports, namely, scientific research in the field of genetics, biology, biotechnology, microbiology, biochemistry and pharmacy; advisory services relating to product testing; product testing; provision of scientific information in the field of genetics, biology, biotechnology, microbiology, biochemistry and pharmacy; scientific research advisory services for others; scientific advisory services for others in the field of genetics, biology, biotechnology, microbiology, biochemistry and pharmacy; scientific and technical analysis, namely, scientific research consulting in the field of genetics, biology, biotechnology, microbiology, biochemistry and pharmacy; scientific and technological services, namely, scientific research, analysis, testing and development in the field of genetics, biology, biotechnology, microbiology, biochemistry and pharmacy; scientific research consulting; scientific laboratory services; analysis of statistical data for scientific research; medical and scientific research, namely, conducting clinical trials for others; medical research, namely, scientific research for medical purposes; scientific and technological research for medical purposes in the field of genetics, biology, biotechnology, microbiology, biochemistry and pharmacy; advisory services relating to scientific research; scientific research and development services in the field of protein bioengineering; advisory services relating to technological research for use in the development of new medicines, pharmaceuticals, immunological products, and therapeutic goods; scientific and technological research relating to patent mapping; technological research in the field of genetics, biology, biotechnology, microbiology, biochemistry and pharmacyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 29, 2024FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 10, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 10, 2024FIMPFINAL DISPOSITION PROCESSED—
Apr 9, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 21, 2024OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jan 9, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 9, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 3, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 3, 2024OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Oct 24, 2023GPNXNOTIFICATION PROCESSED BY IB—
Oct 24, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 24, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 4, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Oct 4, 2023OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Oct 4, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 15, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 25, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 24, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 24, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 11, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 11, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jul 11, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 11, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 11, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 11, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 24, 2023RFNPREFUSAL PROCESSED BY IB—
May 3, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 2, 2023RFRRREFUSAL PROCESSED BY MPU—
Mar 14, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 13, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 10, 2023DOCKASSIGNED TO EXAMINER—
Aug 5, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 1, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 28, 2022LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Jul 28, 2022REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance